Evaluating combinations of modifiable and nonmodifiable risk factors improves risk stratification for late-onset Parkinson disease.

Long-term fumarate therapy for multiple sclerosis, compared with anti-CD20 therapy, is linked to a reduced risk for infection.

ADHD is associated with a significant increase in gastrointestinal symptoms compared with those that do not have ADHD.

There may be a dose-dependent association between eating more whole grains and the reduction of several major cardiovascular risk factors.

Improved cardiovascular health may help manage symptoms of overactive bladder based on a nonlinear association between each factor.

Many suspected poisonings among young children can be handled by a local poison control center despite frequent reliance on ED visits.

The FDA has approved Aqneursa (levacetylleucine) for ataxia in adult and pediatric patients with ataxia-telangiectasia weighing at least 15 kg.

Adults with chronic cough exhibited significant reductions in GMV across multiple brain regions when compared with a healthy control group.

FDA approves Fayuvi (rebisufligene etisparvovec-hopf), the first gene therapy for pediatric patients with mucopolysaccharidosis type IIIA (MPS IIIA).

High pulse pressure and low education levels significantly worsen amyloid-related cognitive decline in adults aged 90 years and older.

High serum glial fibrillary acidic protein levels indicate an increased risk for progression independent of relapse activity in multiple sclerosis.